Sermorelin (GHRH 1-29) is a 29-amino-acid synthetic fragment of growth hormone-releasing hormone — the first GHRH analogue developed for clinical use, FDA-approved in 1997 for GH deficiency in children before being voluntarily discontinued by the manufacturer in 2008 for business reasons (not safety concerns). It remains widely used in peptide therapy clinics and as a research compound, with the longest safety record of any GHRH analogue. Understanding where sermorelin fits relative to modern alternatives — primarily CJC-1295 — is essential for anyone considering GH secretagogue research.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Ipamorelin is the most commonly recommended combination — its selective GH release with minimal cortisol/prolactin elevation combines well with sermorelin's GHRH mechanism. The combination produces synergistic GH pulses through distinct receptor pathways. GHRP-2 and GHRP-6 are alternatives, though GHRP-6's hunger stimulation can be significant at effective doses.
How Does Sermorelin Work?
Sermorelin is the first 29 amino acids of endogenous GHRH (1-44), representing the biologically active core that binds the GHRH receptor (GHRH-R) on pituitary somatotrophs. Receptor binding stimulates somatotroph production and pulsatile GH release in a physiological pattern — preserving the natural pulsatility of GH secretion that continuous GH administration disrupts. This physiological mimicry is central to sermorelin's appeal: it stimulates the pituitary rather than replacing its function.
Sermorelin has a short half-life of approximately 10–20 minutes, meaning its effects are transient and GH pulses it generates are relatively brief. This short duration requires precise timing (administration just before sleep to coincide with the nocturnal GH pulse) and means plasma GH elevation is less sustained than longer-acting GHRH analogues. Bioavailability via subcutaneous injection is approximately 7–12%.
Sermorelin vs CJC-1295: Key Differences
CJC-1295 (without DAC) has an amino acid sequence similar to sermorelin with modifications that increase resistance to enzymatic degradation, extending its half-life to approximately 30–45 minutes. CJC-1295 with DAC (Drug Affinity Complex) extends half-life dramatically further (6–8 days) by covalently binding to albumin. The clinical question is whether longer activity is beneficial or introduces unwanted chronic GH elevation.
Sermorelin's key advantage: its very short half-life produces a clean, physiological GH pulse tightly coupled to administration timing. There is no accumulation, no suppression of endogenous feedback loops from chronic GH elevation, and 40+ years of safety data including human clinical use in children. The disadvantage: it requires more precise timing and may produce less total GH exposure per injection than longer-acting alternatives. For individuals preferring a conservative, clinically-validated approach, sermorelin's track record is unmatched in this category.
Sermorelin Protocols and Dosing
Clinical sermorelin dosing (from FDA prescribing information for paediatric GH deficiency) was 0.03 mg/kg/day (approximately 2–3 mg/day in adults by weight). Research and peptide therapy clinic use typically employs lower doses: 300–600 mcg subcutaneously at bedtime, 5 nights per week. Pre-sleep timing maximises synergy with the nocturnal GH surge and sleep-associated growth hormone release.
Sermorelin is often combined with a GHRP (GHRP-6, GHRP-2, Ipamorelin) to achieve synergistic GH release — GHRH analogues and GHRPs work on separate receptor systems and produce greater than additive GH pulses when combined. The most common research combination is sermorelin 300 mcg + Ipamorelin 300 mcg subcutaneously at bedtime.
Effects and Timeline
Sermorelin's effects develop gradually over weeks to months, consistent with physiological GH elevation rather than supraphysiological exogenous GH. Expected research effects include improved sleep quality (within 1–2 weeks), recovery improvements, body composition changes (lean mass increase, fat reduction) over 3–6 months, and skin quality improvements. IGF-1 levels typically rise moderately — less dramatically than exogenous GH — confirming the physiological rather than pharmacological nature of the GH stimulation.
Unlike exogenous GH, sermorelin does not suppress endogenous GHRH or GH secretion — the pituitary retains its natural feedback regulation. This is considered an important safety advantage, particularly for younger users where pituitary axis integrity is critical.
Sermorelin vs CJC-1295 Comparison
| Factor | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Amino acids | 29 | 30 (modified) | — | — |
| Half-life (no DAC) | 10–20 min | ~30–45 min | — | — |
| Typical dose | 300–600 mcg | 100–300 mcg | — | — |
| Timing | Pre-sleep strictly | Pre-sleep (no DAC) | — | — |
| Clinical data | FDA-approved (1997, disc. 2008) | Research use only | — | — |
| Safety record | Extensive (paediatric data) | Limited (research only) | — | — |
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Sermorelin (Geref) was voluntarily discontinued by Serono in 2008 for commercial, not safety, reasons — the market for paediatric GH deficiency treatment shifted toward recombinant GH (Genotropin, Norditropin), which was more profitable. There were no FDA safety actions associated with its discontinuation.
Sermorelin is not commercially available as a branded drug (Geref was discontinued). It is available from compounding pharmacies through a physician prescription and as a research peptide through vendor channels for research use.
Sermorelin (GHRH analogue) and MK-677 (ghrelin mimetic) work through different receptors but both increase GH and IGF-1. MK-677 is oral, which is a significant practical advantage. Sermorelin produces a more physiological pulsatile GH pattern; MK-677 produces more sustained GH elevation and may cause more pronounced hunger increase. Both are WADA-prohibited.
Ipamorelin is the most commonly recommended combination — its selective GH release with minimal cortisol/prolactin elevation combines well with sermorelin's GHRH mechanism. The combination produces synergistic GH pulses through distinct receptor pathways. GHRP-2 and GHRP-6 are alternatives, though GHRP-6's hunger stimulation can be significant at effective doses.